IL256800B2 - An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy - Google Patents
An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapyInfo
- Publication number
- IL256800B2 IL256800B2 IL256800A IL25680018A IL256800B2 IL 256800 B2 IL256800 B2 IL 256800B2 IL 256800 A IL256800 A IL 256800A IL 25680018 A IL25680018 A IL 25680018A IL 256800 B2 IL256800 B2 IL 256800B2
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- disease
- syndrome
- human
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| US201562197966P | 2015-07-28 | 2015-07-28 | |
| US201662277201P | 2016-01-11 | 2016-01-11 | |
| PCT/US2016/042074 WO2017011544A1 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL256800A IL256800A (en) | 2018-03-29 |
| IL256800B IL256800B (en) | 2022-12-01 |
| IL256800B2 true IL256800B2 (en) | 2023-04-01 |
Family
ID=57757587
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256800A IL256800B2 (en) | 2015-07-14 | 2016-07-13 | An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy |
| IL297907A IL297907B2 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
| IL310460A IL310460A (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297907A IL297907B2 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
| IL310460A IL310460A (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10874738B2 (enExample) |
| EP (2) | EP3331548B1 (enExample) |
| JP (4) | JP6826113B2 (enExample) |
| KR (2) | KR20250099272A (enExample) |
| CN (2) | CN108135969B (enExample) |
| AU (3) | AU2016294417B2 (enExample) |
| CL (1) | CL2018000103A1 (enExample) |
| CO (1) | CO2018001363A2 (enExample) |
| CR (1) | CR20180097A (enExample) |
| DO (1) | DOP2018000018A (enExample) |
| EA (1) | EA201890297A1 (enExample) |
| EC (1) | ECSP18009949A (enExample) |
| GT (1) | GT201800018A (enExample) |
| HK (1) | HK1249735A1 (enExample) |
| IL (3) | IL256800B2 (enExample) |
| MX (2) | MX2018000548A (enExample) |
| MY (2) | MY196991A (enExample) |
| PE (1) | PE20180741A1 (enExample) |
| PH (1) | PH12018500098A1 (enExample) |
| SG (1) | SG10201913431QA (enExample) |
| TN (1) | TN2018000021A1 (enExample) |
| WO (1) | WO2017011544A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
| KR20180080337A (ko) | 2015-11-27 | 2018-07-11 | 아블린쓰 엔.브이. | Ｃｄ40ｌ을 억제하는 폴리펩티드 |
| AU2019247511B2 (en) | 2018-04-06 | 2025-10-16 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| US20210317220A1 (en) * | 2018-09-24 | 2021-10-14 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN115227824A (zh) * | 2018-11-12 | 2022-10-25 | 中南大学湘雅二医院 | 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用 |
| WO2020210831A1 (en) * | 2019-04-12 | 2020-10-15 | TONIX Pharmaceuticals Holding Corp | Inhibitors of cd40-cd154 binding |
| CA3156803A1 (en) * | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| CN113488170B (zh) * | 2021-07-02 | 2023-07-25 | 温州医科大学 | 急性前葡萄膜炎复发风险预测模型构建方法及相关设备 |
| KR20230019798A (ko) * | 2021-07-30 | 2023-02-09 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
| WO2023008982A1 (ko) * | 2021-07-30 | 2023-02-02 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024222895A1 (zh) | 2023-04-28 | 2024-10-31 | 信达生物制药(苏州)有限公司 | 抗cd40l抗体及其在人自身免疫疾病治疗的应用 |
| US20240392022A1 (en) | 2023-05-22 | 2024-11-28 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd40l antibodies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012566A1 (en) * | 1997-09-08 | 1999-03-18 | Idec Pharmaceuticals Corporation | HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF |
| WO2008118356A2 (en) * | 2007-03-22 | 2008-10-02 | Biogen Idec Ma Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2143553T3 (es) | 1993-09-02 | 2000-05-16 | Dartmouth College | Anticuerpos anti-gp39 y sus utilizaciones. |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6444018B1 (en) | 1998-06-25 | 2002-09-03 | Xerox Corporation | Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| PL366307A1 (en) | 2000-10-13 | 2005-01-24 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| EP1639014B1 (en) | 2003-06-13 | 2010-09-22 | Biogen Idec MA Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| CA2832281C (en) * | 2011-04-04 | 2019-11-05 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
-
2016
- 2016-07-13 CR CR20180097A patent/CR20180097A/es unknown
- 2016-07-13 MX MX2018000548A patent/MX2018000548A/es unknown
- 2016-07-13 WO PCT/US2016/042074 patent/WO2017011544A1/en not_active Ceased
- 2016-07-13 EP EP16825103.1A patent/EP3331548B1/en active Active
- 2016-07-13 MY MYPI2018700104A patent/MY196991A/en unknown
- 2016-07-13 IL IL256800A patent/IL256800B2/en unknown
- 2016-07-13 PE PE2018000072A patent/PE20180741A1/es unknown
- 2016-07-13 HK HK18109202.5A patent/HK1249735A1/zh unknown
- 2016-07-13 KR KR1020257020732A patent/KR20250099272A/ko active Pending
- 2016-07-13 TN TNP/2018/000021A patent/TN2018000021A1/en unknown
- 2016-07-13 IL IL297907A patent/IL297907B2/en unknown
- 2016-07-13 EA EA201890297A patent/EA201890297A1/ru unknown
- 2016-07-13 IL IL310460A patent/IL310460A/en unknown
- 2016-07-13 SG SG10201913431QA patent/SG10201913431QA/en unknown
- 2016-07-13 KR KR1020187004571A patent/KR102825142B1/ko active Active
- 2016-07-13 EP EP26164394.4A patent/EP4732909A2/en active Pending
- 2016-07-13 JP JP2018521475A patent/JP6826113B2/ja active Active
- 2016-07-13 CN CN201680053004.3A patent/CN108135969B/zh active Active
- 2016-07-13 CN CN202210146798.5A patent/CN114671952A/zh active Pending
- 2016-07-13 US US15/744,379 patent/US10874738B2/en active Active
- 2016-07-13 AU AU2016294417A patent/AU2016294417B2/en active Active
- 2016-07-13 MY MYPI2020006781A patent/MY203911A/en unknown
-
2018
- 2018-01-11 PH PH12018500098A patent/PH12018500098A1/en unknown
- 2018-01-12 GT GT201800018A patent/GT201800018A/es unknown
- 2018-01-12 MX MX2023014921A patent/MX2023014921A/es unknown
- 2018-01-12 DO DO2018000018A patent/DOP2018000018A/es unknown
- 2018-01-12 CL CL2018000103A patent/CL2018000103A1/es unknown
- 2018-02-09 EC ECIEPI20189949A patent/ECSP18009949A/es unknown
- 2018-02-12 CO CONC2018/0001363A patent/CO2018001363A2/es unknown
-
2020
- 2020-11-23 US US17/101,139 patent/US11596689B2/en active Active
-
2021
- 2021-01-13 JP JP2021003152A patent/JP2021063129A/ja active Pending
-
2022
- 2022-11-02 AU AU2022263520A patent/AU2022263520B2/en active Active
-
2023
- 2023-02-01 US US18/162,769 patent/US20240000929A1/en active Pending
- 2023-07-05 JP JP2023110414A patent/JP7605914B2/ja active Active
-
2024
- 2024-12-12 JP JP2024217195A patent/JP2025038055A/ja active Pending
-
2025
- 2025-09-05 AU AU2025226796A patent/AU2025226796A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012566A1 (en) * | 1997-09-08 | 1999-03-18 | Idec Pharmaceuticals Corporation | HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF |
| WO2008118356A2 (en) * | 2007-03-22 | 2008-10-02 | Biogen Idec Ma Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022263520B2 (en) | Anti-CD154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
| US20220324996A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| US9683044B2 (en) | Molecules with antigen binding and polyvalent FC gamma receptor binding activity | |
| CA2992116C (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
| EA051762B1 (ru) | Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека | |
| BR112018000653B1 (pt) | Anticorpo anti-cd154 humano, composição farmacêutica e usos dos mesmos | |
| HK40089590A (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| EA040553B1 (ru) | Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека |